BDR Group

BDR Group is a Mumbai-based pharmaceutical company focusing on the development and distribution of oncology and supportive care therapies, providing high-quality generic medications to enhance patient care. Founded in 2003 and headquartered in Mumbai, India, BDR Group specializes in pharmaceutical development and distribution. The company has strategically pivoted to focus on oncology and supportive care, securing significant investment through a BUYOUT in May 2022 valued at INR 6. 85 billion, led by Multiples Alternate Asset Management.

Under the leadership of CEOs Aaron Gamma, Elsayed Wezza, and Tiago de Camargo, the company has successfully executed one deal to date, with this round bringing their total amount raised to INR 6. 85 billion. BDR Pharma specializes in the development and distribution of pharmaceutical products, primarily in oncology and supportive care therapies. The company offers a range of high-quality generic medications designed to treat various forms of cancer, addressing critical needs in patient care.

Their products also include supportive therapies aimed at managing side effects associated with cancer treatments. BDR Pharma serves a diverse client base, including hospitals, clinics, and healthcare providers, primarily in key international markets such as the United States, Europe, and parts of Asia. The products meet stringent regulatory standards, ensuring efficacy and safety for patients undergoing cancer treatment. For the most recent fiscal year 2023, BDR Pharma reported a revenue of INR 24,810,927.

30 and an EBITDA of INR 3,928,376. 60. The company generates revenue through direct sales and partnerships with healthcare institutions, primarily through long-term contracts with hospitals and healthcare providers, structured to allow for predictable revenue streams. Following the recent funding round completed in May 2022, BDR Group aims to enhance its research and development capabilities and expand its manufacturing capacity.

The company is also scouting for acquisition opportunities to further its growth. Future plans include launching new products targeted for oncology therapies and expanding into new geographic markets, notably aiming to strengthen its presence in Europe and Asia by 2024.